Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of gepotidacin versus ceftriaxone plus azithromycin for uncomplicated urogenital gonorrhea
2018-001780-23Phase 3Unknown
- Sponsor
- GSK
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gonorrhea and gonococcal proctitis comparing Gepotidacin with Ceftriaxone plus azithromycin (2 arms). Primary endpoint: Culture-confirmed bacterial eradication of Neisseria gonorrhoeae from the urogenital body site. Status: unknown.
02
Drugs
gepotidacinceftriaxoneazithromycin
03
Conditions
gonorrheagonococcal proctitis
Beyond the preview
Go deeper on 2018-001780-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001780-23.